MCID: STR005
MIFTS: 15

Stork Bite

Categories: Cardiovascular diseases, Cancer diseases

Aliases & Classifications for Stork Bite

MalaCards integrated aliases for Stork Bite:

Name: Stork Bite 12 15
Salmon Patch Nevus 12
Unna's Nevus 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5806

Summaries for Stork Bite

MalaCards based summary : Stork Bite, is also known as salmon patch nevus. An important gene associated with Stork Bite is RASA1 (RAS P21 Protein Activator 1). The drugs Timolol and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include skin.

Related Diseases for Stork Bite

Symptoms & Phenotypes for Stork Bite

Drugs & Therapeutics for Stork Bite

Drugs for Stork Bite (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 120)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Timolol Approved Phase 3,Phase 2,Phase 1,Early Phase 1 26839-75-8 33624 5478
2
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1,Not Applicable 22916-47-8 4189
3
Propranolol Approved, Investigational Phase 2, Phase 3,Phase 3 525-66-6 4946
4
Everolimus Approved Phase 2, Phase 3,Phase 1,Not Applicable 159351-69-6 6442177
5
Nadolol Approved Phase 3,Phase 2 42200-33-9 39147
6
Sirolimus Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 53123-88-9 5284616 6436030 46835353
7
Atenolol Approved Phase 3 29122-68-7 2249
8
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
9
Acebutolol Approved, Investigational Phase 3 37517-30-9 1978
10 tannic acid Approved, Nutraceutical Phase 3
11 Adrenergic Agents Phase 3,Phase 2,Phase 1,Early Phase 1
12 Adrenergic Antagonists Phase 3,Phase 2,Phase 1,Early Phase 1
13 Adrenergic beta-Antagonists Phase 3,Phase 2,Phase 1,Early Phase 1
14 Neurotransmitter Agents Phase 3,Phase 2,Phase 1,Early Phase 1
15 Anti-Arrhythmia Agents Phase 3,Phase 2,Phase 1,Early Phase 1
16 Pharmaceutical Solutions Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1
17 Antihypertensive Agents Phase 3,Phase 2,Phase 1,Early Phase 1
18 Sympatholytics Phase 3,Phase 2
19 Vasodilator Agents Phase 2, Phase 3,Phase 3
20 Peripheral Nervous System Agents Phase 3,Phase 2
21 Anti-Bacterial Agents Phase 2, Phase 3,Phase 1,Not Applicable
22 Antibiotics, Antitubercular Phase 2, Phase 3,Phase 1,Not Applicable
23 Immunosuppressive Agents Phase 2, Phase 3,Phase 1,Not Applicable
24 Anti-Infective Agents Phase 2, Phase 3,Phase 1,Not Applicable
25 Antifungal Agents Phase 2, Phase 3,Phase 1,Not Applicable
26 Autonomic Agents Phase 3,Phase 2
27 Brimonidine Tartrate Phase 3 70359-46-5
28 Adrenergic Agonists Phase 3
29 Adrenergic alpha-2 Receptor Agonists Phase 3
30 Adrenergic alpha-Agonists Phase 3
31 Adrenergic beta-1 Receptor Antagonists Phase 3
32
Bosentan Approved, Investigational Phase 2 147536-97-8 104865
33
Imiquimod Approved, Investigational Phase 2,Not Applicable 99011-02-6 57469
34
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
35
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
36
Bleomycin Approved, Investigational Phase 2 11056-06-7 5360373
37
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
38
Ranitidine Approved Phase 2 66357-59-3, 66357-35-5 3001055
39 Strawberry Approved, Nutraceutical Phase 2
40
Maleic acid Experimental Phase 2,Phase 1 110-16-7 444266
41 interferons Phase 2,Not Applicable
42 glucocorticoids Phase 2
43 Adjuvants, Immunologic Phase 2,Not Applicable
44 Hormone Antagonists Phase 2
45 Hormones Phase 2
46 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
47 Endothelin Receptor Antagonists Phase 2
48 Interferon Inducers Phase 2,Not Applicable
49 Anti-Inflammatory Agents Phase 2
50 Antineoplastic Agents, Hormonal Phase 2

Interventional clinical trials:

(show top 50) (show all 68)
# Name Status NCT ID Phase Drugs
1 A Pilot Study of Hemoporfin PDT in Children With Port-wine Stain Recruiting NCT03125057 Phase 4 Hemoporfin PDT
2 Postmarketing Safety Study of Hemoporfin in Patients With Port Wine Stain Recruiting NCT03181984 Phase 4 Hemoporfin
3 Treatment of Port Wine Stains in Children With Pulsed Dye Laser and Timolol Gel Unknown status NCT01272609 Phase 3 Timolol + LCP
4 Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy Completed NCT01056341 Phase 2, Phase 3 Propranolol;Placebo
5 Onreltea (Brimonidine) Gel In Pediatric Patients With Capillary Malformations Recruiting NCT02764411 Phase 3 Brimonidine 0.33% gel
6 Comparative Study to Evaluate the Effectiveness of Atenolol and Propranolol in the Treatment of Infantile Hemangiomas Recruiting NCT03237637 Phase 3 oral propranolol;oral atenolol
7 Nadolol Versus Propranolol in Children With Infantile Hemangiomas Recruiting NCT02505971 Phase 3 Nadolol;Propranolol
8 Efficacy and Safety of Propranolol Versus Atenolol on the Proliferative Phase of Infantile Hemangioma Recruiting NCT02342275 Phase 3 Propranolol;Atenolol
9 Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome Recruiting NCT03047980 Phase 2, Phase 3 Sirolimus
10 Effectiveness and Safety of Intense Pulsed Light in Patients With Meibomian Gland Dysfunction Not yet recruiting NCT03518398 Phase 3
11 Efficacy and Safety of Propranolol Versus Acebutolol on the Proliferative Phase of Infantile Hemangioma Terminated NCT01743885 Phase 3 Acebutolol;Propanolol
12 Propranolol in Capillary Hemangiomas Terminated NCT00744185 Phase 2, Phase 3 propranolol treatment;placebo treatment
13 Topical Timolol for Infantile Hemangioma in Early Proliferative Phase Unknown status NCT02731287 Phase 2 Timolol;Placebo
14 Treatment of Resistant Port-wine Stains With Bosentan and Pulsed Dye Laser: a Pilot Study Completed NCT02317679 Phase 2 Bosentan
15 Measurement Skin Temperature During Pulsed Laser Exposure Completed NCT00540917 Phase 2
16 Topical Timolol Gel for the Treatment of Infantile Hemangiomas Completed NCT02145884 Phase 2 timolol maleate 0.5% gel
17 Study in Infants With Infantile Hemangioma to Compare Propranolol Gel to Placebo Completed NCT01512173 Phase 2 propranolol gel;Placebo
18 Comparative Study of the Use of Beta Blocker and Oral Corticosteroid in the Treatment of Infantile Hemangioma Completed NCT01072045 Phase 2 Propranolol;Prednisone
19 Nadolol for Proliferating Infantile Hemangiomas Completed NCT01010308 Phase 2 Nadolol
20 A Phase II Study of Imiquimod 5 % Cream for the Treatment of Hemangioma in Infancy Completed NCT00601016 Phase 2 Imiquimod 5% cream
21 Electrosclerotherapy for Capillary Malformations Recruiting NCT02883023 Phase 2 Intralesional bleomycin injection
22 Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH) Recruiting NCT02913612 Phase 2 0.25% Timolol Maleate Gel Forming Solution;0.5% Timolol Maleate Gel Forming Solution
23 The Effects of Aldara as an Adjunct to Laser Treatment Terminated NCT00979550 Phase 2 Imiquimod;non-medicated petroleum cream
24 Corticosteroids With Placebo Versus Corticosteroids With Propranolol Treatment of Infantile Hemangiomas (IH) Terminated NCT01074437 Phase 2 Prednisolone (Corticosteroid);Propranolol;Placebo
25 Combined Use of Pulsed Dye Laser and Topical Antiangiogenic Agents for Treatment of Port Wine Stain Birthmarks Withdrawn NCT00969397 Phase 1, Phase 2 Topical Antiangiogenic
26 Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS) Withdrawn NCT01997255 Phase 2 Everolimus
27 Timolol Option for Ulcerated Hemangiomas (TOUCH Trial) Withdrawn NCT01408056 Phase 2 Timolol 0.5% Gel Forming Solution (GFS);Mupirocin 2% Ointment
28 A Randomized Trial to Study Combined Pulsed Dye Laser and Rapamycin Treatment of Port Wine Stain Birthmarks. Completed NCT00800722 Phase 1 Rapamycin Treatment of Port Wine Stain
29 A Randomized Trial to Study Combined Pulsed Dye Laser and Rapamycin Treatment of Port Wine Stain Birthmarks. Completed NCT00830466 Phase 1 Laser and rapamycin versus laser alone
30 Pulsed Dye Laser Treatment of Port Wine Stain Birthmarks: Comparison of 577 nm Versus 595 nm Wavelengths Completed NCT00573729 Phase 1
31 Treatment of Vascular Lesions With a Tandem 532/1064 nm Laser Completed NCT00585338 Phase 1
32 Optical Clearing of the Skin in Conjunction With Laser Treatments Completed NCT00580736 Phase 1
33 Novel Treatment for Port Wine Stain Birthmarks Recruiting NCT01924273 Phase 1 Talaporfin sodium
34 Timolol for the Prevention of Proliferation of Infantile Hemangioma (TiPPIH Trial) Terminated NCT01434849 Phase 1 topical 0.5% Timolol maleate;Control (placebo) group
35 Combined Alexandrite and Pulsed Dye Laser Treatment of Port Wine Stain Birthmarks Withdrawn NCT00580944 Phase 1
36 Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks Withdrawn NCT00667472 Phase 1 Ranibizumab
37 Pilot Study on the Use of the Matrix Radiofrequencyfor Treatment of Port Wine Stain Birthmarks Withdrawn NCT01166919 Phase 1
38 The Angioma's Treatment Evaluation With Laser Doppler Imaging (LDI) Unknown status NCT01759082
39 Evaluation and Optimization of the Technical and Clinical Performance of the Lumenis ONE Platform Unknown status NCT00247299 Not Applicable
40 Assessing the Effects of Air-cooling on Capillary Malformations Unknown status NCT01735734
41 Monitoring the Response of Port Wine Stain Birthmarks to Laser Therapy With Wide-field Functional Imaging Technologies Completed NCT01333553
42 Dynamic Epidermal Cooling During Pulsed Dye Laser Treatment of Port Wine Stain Birthmark at High Fluences Completed NCT00540371
43 Port Wine Stains Treatment Matrix RF Study Completed NCT01101360 Not Applicable
44 Combined Photodynamic and Pulsed Dye Laser Treatment of Port Wine Stains Completed NCT00556946 Not Applicable Combined Photodynamic & Pulsed Dye Laser Treatment
45 Evaluate the Port-wine Stain Birthmark Treatment Before and After Pulsed Dye Laser Treatment Completed NCT01774552
46 Combined Bipolar Radiofrequency&Pulsed Dye Laser Treatment Completed NCT01775722 Not Applicable
47 Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks Completed NCT00585247 Not Applicable Imiquimod
48 Treatment of Nevus Flammeus With Alexandrite Laser Completed NCT01968681 Not Applicable
49 Treatment of Naevus Flammeus Using Intense Pulsed Light and Pulsed Dye Laser Completed NCT00365118 Not Applicable
50 Incidence of Ocular Antibodies in Patients With Sturge - Weber Syndrome (SWS) Completed NCT00610402

Search NIH Clinical Center for Stork Bite

Genetic Tests for Stork Bite

Anatomical Context for Stork Bite

MalaCards organs/tissues related to Stork Bite:

41
Skin

Publications for Stork Bite

Articles related to Stork Bite:

# Title Authors Year
1
Can you catch Ebola from a stork bite? Inductive reasoning influences generalization of perceived zoonosis risk. ( 29117192 )
2017
2
Erythema occipitalis traumaticum and stork bite. ( 8190673 )
1994

Variations for Stork Bite

Expression for Stork Bite

Search GEO for disease gene expression data for Stork Bite.

Pathways for Stork Bite

GO Terms for Stork Bite

Sources for Stork Bite

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....